Mylan, Matrix Join Forces To Slash Prices Of AIDS, TB Drugs
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Mylan and Pfizer plan to drastically lower prices for second-line HIV/AIDS and tuberculosis drugs used in developing countries following an agreement with the Clinton Foundation
You may also be interested in...
Shanghai Pharmaceutical (Group), Science And Technology Commission Collaborate On Drug Research
Shanghai Pharmaceutical (Group), China's largest pharmaceutical company, has signed an agreement with the Science and Technology Commission of Shanghai Municipality to promote deep integration between industry, academia and clinical research. Both parties will jointly invest and set up a research fund for the pharmaceutical group's new drug research and development, quality improvement, as well as development of new clinical applications for existing drugs. With its comprehensive coverage, SPG is leading Shanghai's latest biopharmaceutical push (PharmAsia News, Aug. 10, 2009). The company has identified 10 key products for redevelopment and plans to invest RMB 1.15 billion in new drug R&D and new technology platforms over the next three years. STCSM will initially review candidate projects and conduct post-implementation evaluations. (Click here for more - Chinese Language)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).